Patient-reported outcomes in multiple myeloma.

Area of Science:

• Hematology
• Oncology
• Patient-Reported Outcomes

Background:

• Multiple myeloma is an incurable plasma cell malignancy with diverse, debilitating symptoms.
• Disease progression involves bone destruction, marrow infiltration, renal failure, and immunodeficiency.
• Psychosocial burden significantly impacts patients' quality of life.

Purpose of the Study:

• To highlight the importance of symptom palliation and life prolongation in multiple myeloma care.
• To emphasize the need to balance treatment toxicity with disease control.
• To underscore the growing significance of patient-reported outcomes (PROs) in evaluating cancer treatment.

Main Methods:

• Review of existing literature on multiple myeloma symptoms and treatments.
• Analysis of traditional clinical trial endpoints (response rates, survival).
• Examination of the role and application of patient-reported measures in myeloma research.

Main Results:

• New therapies offer improved disease control but may cause significant side effects.
• Traditional objective measures do not fully capture the patient experience.
• PROs provide crucial insights into the real-world impact of myeloma and its treatments.

Conclusions:

• Symptom management and quality of life are paramount in multiple myeloma treatment.
• A comprehensive assessment requires integrating objective data with subjective patient experiences.
• Patient-reported measures are essential for a holistic understanding of treatment benefits and risks.